BioSpecifics Technologies Corp (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a collagenase-based product marketed as XIAFLEX in the US and Xiapex in Europe, announced on Friday its financial results for the third quarter ended 30 September 2018.
The company reported net income of USD5m, or USD0.69 per basic share and USD0.69 per share on a fully diluted basis, for the third quarter ended 30 September 2018, compared to net income of USD2.7m or USD0.38 per basic share and USD0.37 per share on a fully diluted basis, in the same period in 2017.
The firm posted total revenue for the third quarter ended 30 September 2018 at USD8.2m compared to USD6.5m in the year-ago period.
As of 30 September 2018, BioSpecifics had cash and cash equivalents and investments of USD77.0m, compared to USD65.1m as of 31 December 2017.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government